StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a report released on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Aptevo Therapeutics Price Performance
Shares of APVO stock opened at $4.06 on Monday. Aptevo Therapeutics has a twelve month low of $3.81 and a twelve month high of $92.62. The firm has a 50-day moving average price of $6.12 and a 200 day moving average price of $9.24.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of APVO. Dimensional Fund Advisors LP purchased a new stake in shares of Aptevo Therapeutics in the fourth quarter valued at $29,000. Virtu Financial LLC purchased a new stake in Aptevo Therapeutics in the 2nd quarter valued at about $46,000. Citadel Advisors LLC acquired a new position in shares of Aptevo Therapeutics during the 4th quarter valued at about $47,000. Renaissance Technologies LLC increased its stake in shares of Aptevo Therapeutics by 45.8% during the 2nd quarter. Renaissance Technologies LLC now owns 80,186 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 25,200 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in shares of Aptevo Therapeutics during the 1st quarter worth about $152,000. 8.06% of the stock is currently owned by institutional investors and hedge funds.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.
Read More
- Five stocks we like better than Aptevo Therapeutics
- Stock Market Upgrades: What Are They?
- Best Bear Market Funds: Top 3 Investment Options to Consider
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- What Does Downgrade Mean in Investing?
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.